Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) NSCLC
NCT00924209Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2009
- Primary completion
- Sep 2011
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Mar 2009; status: terminated.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00924209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00924209.